title: [Hepatitis C virus: therapeutic targets and new drugs].
abstract: The viral and patient factors affecting the efficacy of therapy were discussed. The modern data on the molecular mechanism of action of main drugs for hepatitis C therapy were presented. New antiviral drugs (protease inhibitors) and pharmacological substances under development targeted against viral polymerase and protein NS5A were considered.
authors.forename: L I
authors.initials: LI
authors.lastname: Nikolaeva
authors.forename: G V
authors.initials: GV
authors.lastname: Sapronov
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D054316:Biomarkers, Pharmacological; D012321:DNA-Directed RNA Polymerases / Q000037:antagonists & inhibitors / Q000378:metabolism; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D016174:Hepacivirus / Q000187:drug effects / Q000472:pathogenicity; D006526:Hepatitis C / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D006801:Humans; D007371:Interferon-gamma / Q000235:genetics; D058990:Molecular Targeted Therapy; D011480:Protease Inhibitors / Q000627:therapeutic use*; D012254:Ribavirin / Q000627:therapeutic use; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D012324:RNA-Dependent RNA Polymerase
chemical_list: D000998:Antiviral Agents; D054316:Biomarkers, Pharmacological; D012321:DNA-Directed RNA Polymerases; D003841:Deoxycytidine; D007371:Interferon-gamma; D011480:Protease Inhibitors; D012254:Ribavirin; D017361:Viral Nonstructural Proteins; C552098:2'-fluoro-2'-methyl-3',5'-diisobutyryldeoxycytidine; C087036:NS-5 protein, hepatitis C virus; D012324:RNA-Dependent RNA Polymerase